Effect of ilomastat combined with capecitabine on human laryngeal cancer hep-2 cell*
	    		
		   		
		   			
		   		
	    	
    	 
    	10.3969/j.issn.1671-8348.2013.27.025
   		
        
        	
        		- VernacularTitle:伊洛马司他联合卡培他滨对人喉癌hep-2细胞的影响
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Li LI
			        		
			        		;
		        		
		        		
		        		
			        		Shaogrong ZHANG
			        		
			        		;
		        		
		        		
		        		
			        		Huiqiang XIONG
			        		
			        		;
		        		
		        		
		        		
			        		Shufeng GAO
			        		
			        		;
		        		
		        		
		        		
			        		Ning LAN
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		laryngeal neoplasms;
			        		
			        		
			        		
				        		ilomastat;
			        		
			        		
			        		
				        		capecitabine
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			Chongqing Medicine
	            		
	            		 2013;(27):3269-3271,3274
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Objective To explore the effect of ilomastat combined with chemotherapeutic drug capecitabine on human laryngeal cancer hep-2 cell .Methods hep-2 cells were treated by ilomastat and capecitabine alone and their combination .The untreated group was taken as the control group .The proliferation activity of the hep-2 cells was analyzed by MTT assay ,and the Jin′s Q was adopt-ed to assess the characters of combination medication of ilomastat and capecitabine ;the expression level of MMP-9mRNA in hep-2 cell was detected by RT-PCR;the apoptosis rate of hep-2 cell was detected by the flow cytometry .Results Both ilomastat and capecitabine had the inhibiting effect on the proliferation of hep-2 cell ,and the combination of ilomastat and capecitabine increased the cell inhibitory rate(P<0 .05) ,the interaction between ilomastat and capecitabine was the synergistic effect when the combined concentration was (8+100)μg/mL ,while the interaction between ilomastat and capecitabine was the additive action when the com-bined concentration was (40+ 400)μg/mL ;RT-PCR analysis showed that compared with control group ,the expression level of MMP-9mRNA in the single ilomastat group and the combination group were both decreased (P< 0 .05) ,and the expression of MMP-9mRNA in the combination group was lower than that in the single ilomastat group (P<0 .05);the flow cytometry indicated that the apoptosis rate of hep-2 cell in the single ilomastat group and the single capecitabine group were both higher than that in the control group(P<0 .05) ,and the apoptosis rate in the combination group was higher than that in the other groups (P<0 .05) .Con-clusion Ilomastat combined with capecitabine can obviously enhance the inhibition and apoptosis-induced ability of single drug on laryngeal cancer hep-2 cell ,the action mechanism of ilomastst is down-regulation of the expression level of the MMP-9 mRNA .